Literature DB >> 6731328

Göteborg Metoprolol Trial: clinical observations.

J Herlitz, M Hartford, K Pennert, F Waagstein, A Waldenström, H Wedel, C Wilhelmsson, A Hjalmarson.   

Abstract

Heart rate, systolic blood pressure and rate-pressure product were analyzed during the first 18 hours and 4 days after intravenous metoprolol or placebo. On injection of metoprolol there was an immediate decrease in mean heart rate from 72.9 +/- 0.6 to 62.7 +/- 0.4 beats/min, but no change was found in the placebo group. The difference in heart rate remained during the first 4 days. Systolic blood pressure was reduced from 144.1 +/- 0.9 to 134.6 +/- 0.9 mm Hg after intravenous metoprolol and was lower than that in the placebo group during 4 days of follow-up. Indirect signs of congestive heart failure tended to be less severe in patients given metoprolol within 12 hours of the onset of symptoms than in those given placebo. The duration of hospitalization also tended to be shorter in patients given early metoprolol treatment than in those given placebo early.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6731328

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo.

Authors:  C Risøe; O J Kirkeby; P Grøttum; M Sederholm; J K Kjekshus
Journal:  Br Heart J       Date:  1987-01

Review 2.  Beta-blockers after acute myocardial infarction in elderly patients with diabetes mellitus: time to reassess.

Authors:  Mauro Di Bari; Niccolò Marchionni; Marco Pahor
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Free radical scavenging properties of beta-adrenoceptor blockers are not relevant for cardioprotection in isolated rabbit hearts.

Authors:  A F Rump; R Rösen; W Klaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

Review 4.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.